Sphingomyelin and Medullary Sponge Kidney Disease: A Biological Link Identified by Omics Approach

Simona Granata1, Maurizio Bruschi2, Michela Deiana3

  • 1Renal Unit, Department of Medicine, University-Hospital of Verona, Verona, Italy.

Frontiers in Medicine
|June 14, 2021
PubMed

Insights

Medullary sponge kidney disease (MSK) shows a distinct metabolic profile, with sphingomyelin levels significantly altered. This finding highlights sphingomyelin

Area of Science:

  • Nephrology
  • Metabolomics
  • Proteomics

Background:

  • Medullary sponge kidney disease (MSK) is a rare kidney malformation.
  • Its physiopathology, particularly metabolic alterations, remains incompletely understood.
  • MSK is characterized by nephrocalcinosis and recurrent kidney stones.

Purpose of the Study:

  • To elucidate the metabolic and proteomic alterations in medullary sponge kidney disease (MSK).
  • To identify a specific metabolomic signature for MSK.
  • To investigate the role of sphingomyelin metabolism in MSK pathogenesis.

Main Methods:

  • Collected plasma and urine samples from MSK patients and controls with idiopathic calcium nephrolithiasis (ICN).
  • Performed untargeted plasma metabolomics using UHPLC-ESI-MS/MS.
  • Analyzed urinary microvesicle proteomic data focusing on sphingomyelin metabolism and validated findings by ELISA.

Main Results:

  • Identified 13 metabolites differentiating MSK from ICN, with sphingomyelin being a key discriminant (p < 0.001).
  • Found significant alterations in urinary proteins ENPP6 and SPP1 in MSK patients (p < 0.001).
  • Confirmed increased plasma ENPP6 levels in MSK patients via ELISA.

Conclusions:

  • Revealed a unique high-throughput metabolomics signature for medullary sponge kidney disease (MSK).
  • Indicated a crucial role for sphingomyelin metabolism in the disease's biological pathways.
  • Highlighted potential diagnostic biomarkers for MSK.